MENU
+Compare
DMAC
Stock ticker: NASDAQ
AS OF
Apr 24, 01:10 PM (EDT)
Price
$4.10
Change
+$0.14 (+3.54%)
Capitalization
166.28M

DMAC DiaMedica Therapeutics Forecast, Technical & Fundamental Analysis

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company... Show more

Industry: #Biotechnology
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for DMAC with price predictions
Apr 23, 2025

Momentum Indicator for DMAC turns positive, indicating new upward trend

DMAC saw its Momentum Indicator move above the 0 level on April 21, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 98 similar instances where the indicator turned positive. In of the 98 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where DMAC's RSI Oscillator exited the oversold zone, of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for DMAC just turned positive on April 14, 2025. Looking at past instances where DMAC's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where DMAC advanced for three days, in of 258 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DMAC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

DMAC broke above its upper Bollinger Band on April 23, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for DMAC entered a downward trend on April 16, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.168) is normal, around the industry mean (14.056). P/E Ratio (0.000) is within average values for comparable stocks, (63.446). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.788). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (252.992).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. DMAC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DMAC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

DMAC is expected to report earnings to rise 11.11% to -20 cents per share on May 20

DiaMedica Therapeutics DMAC Stock Earnings Reports
Q1'25
Est.
$-0.20
Q4'24
Missed
by $0.01
Q3'24
Beat
by $0.01
Q2'24
Beat
by $0.03
Q1'24
Beat
by $0.02
The last earnings report on March 17 showed earnings per share of -18 cents, missing the estimate of -17 cents. With 23.17K shares outstanding, the current market capitalization sits at 166.28M.
A.I. Advisor
published General Information

General Information

a developer of novel therapeutic compounds for diabetes and other diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
301 Carlson Parkway
Phone
+1 763 496-5454
Employees
19
Web
https://www.diamedica.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MFWLX16.40N/A
N/A
MFS Global Total Return R6
QISGX23.76N/A
N/A
Federated Hermes MDT Small Cap Growth IS
PVIVX42.08N/A
N/A
Paradigm Micro-Cap
SVFFX68.70N/A
N/A
Smead Value I1
LOAGX14.03N/A
N/A
Lord Abbett International Growth F3

DMAC and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, DMAC has been loosely correlated with WHWK. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if DMAC jumps, then WHWK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DMAC
1D Price
Change %
DMAC100%
+2.06%
WHWK - DMAC
43%
Loosely correlated
+0.65%
VTGN - DMAC
29%
Poorly correlated
+5.85%
DSGN - DMAC
28%
Poorly correlated
+2.78%
ATYR - DMAC
28%
Poorly correlated
+0.86%
BHVN - DMAC
28%
Poorly correlated
+1.28%
More